Immuron Ltd cash flow statement

In fiscal 2026, Immuron Ltd's operations generated −$2.2m of cash; it spent $3,227 on capital projects, leaving free cash flow of −$2.2m.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Immuron Ltd: cash flow statement, annual
Fiscal year	2016Jun 2016	2017Jun 2017	2018Jun 2018	2019Jun 2019	2020Jun 2020	2021Jun 2021	2022Jun 2022	2023Jun 2023	2024Jun 2024	2025Jun 2025	2026Jun 2026
Cash from operations	−3,760	−5,238	−2,717	−1,287	−2,112	−3,048	−2,284	−1,747	−3,855	−3,976	−2,213
Depreciation and amortisation	3	4	4	4	30	33	31	33	30	32	29
Stock-based pay	−1,516	394	46	961	49	—	69	153	2	197	60
Capital spending	2	4	5	1	1	5	7	5	0	—	3
Free cash flow	−3,762	−5,242	−2,722	−1,288	−2,113	−3,052	−2,291	−1,752	−3,855	—	−2,217
Free cash flow after stock pay	−2,246	−5,636	−2,769	−2,249	−2,162	—	−2,360	−1,905	−3,857	—	−2,277

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: IMRN vs IVA IMRN vs TSHA ANL vs IMRN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Immuron Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Immuron Ltd.